Background: In order to assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This, in turn, requires that cost data be regularly updated. Objective and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HRQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in EUR 2015. Results: A total of 535 patients (mean age 48.5 years) participated; 92% were below retirement age and of these, 43% were employed. Employment was related to disease severity, and MS was felt to affect productivity at work by 72% of patients, most often through fatigue. Overall, 98% and 74% of patients felt that fatigue and cognition were a problem. Mean utility and costs were 0.756 and €16,500 at the Expanded Disability Status Scale (EDSS) 0-3, 0.572 and €28,700 at EDSS 4-6.5 and 0.206 and €34,400 at EDSS 7-9. The average cost of a relapse was estimated at €2930. Conclusion: This study illustrates the burden of MS on Portuguese patients and provides current data that are important for the development of health policies.
Introduction
Portugal was one of the first countries in Europe to include economic evaluation into decisions about reimbursement and pricing. The National Authority of Medicines and Health Products (Infarmed) issued specific guidelines as early as 1998. 1 Despite this, no comprehensive assessment of the burden of multiple sclerosis (MS) has been published so far.
The availability of disease-modifying treatments (DMTs) has led not only to changes in patient management but also to focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 2 The prevalence of MS in Portugal has been recently estimated at around 56.2 per 100,000, 3 and the vast majority of patients are followed in hospitals of the National Health Service. With earlier diagnosis after a clinically isolated event, 4 one must also expect a different distribution of the type of MS and the severity of the disease: a larger proportion of patients with relapsing-remitting multiple sclerosis (RRMS) disease and thus of patients in the early stages of the disease, with less disability.
It is therefore important to update the information on the burden of MS, and this study is part of a Europeanwide effort in 16 countries, endorsed by the European Platform of MS Societies (EMSP) and carried out with the support of national MS societies. 5 It uses a similar methodology as the last European survey in 2005 that, however, did not include Portugal. 6 
Materials and methods
The detailed methodology of the European survey is published separately. 7 We therefore only provide a short summary of the general methods and issues specific to Portugal.
Data
The study aimed to estimate all costs related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and tests, medication, community care, family support and production losses (sick leave, early retirement, invalidity). In addition, information on major symptoms such as fatigue and cognition using visual analogue scales (VAS), health-related quality of life (HRQoL), as well as self-assessed disability using descriptions based on the Expanded Disability Status Scale (EDSS) were included.
Data were collected with a standard questionnaire, at a single point in time, for a retrospective period of time. The latter was varied depending on the question in order to minimise recall bias: 1 month for use of drugs, community services and family help; 3 months for hospitalisation, consultations, tests, sick leave and relapses; and 12 months for major investments. Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EuroQol-5 dimensions (EQ-5D) 8 ), symptoms (fatigue, cognition) and the effect of MS on work related to the current week. For comparability across countries, utilities are estimated with the original value set developed in the United Kingdom. 9 In Portugal, a specific national value set as well as population norms were established very recently, and we therefore also present utilities established with the local tariff. 10, 11 Costs Costs are calculated from the societal perspective, including all costs regardless of who ultimately is responsible for them. Patient co-payments and patients' out-of-pocket expenses are thus included.
The cost of a relapse is calculated as the difference in quarterly costs between patients with or without a relapse and an EDSS score between 0 and 6. Patients who were unsure were excluded from the estimation. Invalidity, early retirement and DMT costs are not considered in this calculation, as they are unlikely to be affected within 3 months.
Unit costs for the individual resources were taken from public sources and are reported in the paper on methodology. 6 Results are reported in 2015 EUR.
Patients
The objective was to include a sample where all levels of disease severity (defined by EDSS) were represented in sufficient numbers to allow analysis. This highlights how costs and HRQoL change as the disease progresses and provides the necessary data for cost-effectiveness analysis of treatments that are expected to change the course of the disease. As a consequence, our study population does not represent national prevalence of MS in Portugal and mean results for the sample are not meaningful. They can neither be extrapolated to national costs without careful adjustment, nor can they be compared directly to the results in other studies. We therefore report results by disease severity only.
Data collection
In anonymous surveys, participation will depend heavily on the methods used: collecting data in clinical MS centres tends to overestimate the number of patients with early but severe disease and those on treatment with DMTs; collecting data from members in a patient organisation may be influenced by the structure and the activities of the organisation. Internet surveys will bias towards younger patients and those with better education, while postal mailings may bias towards older patients. In Portugal, the vast majority of patients participating were members of the Sociedade Portuguesa de Esclerose Múltipla (SPEM), but a small number was recruited in a clinical centre.
The Portuguese data were collected between October 2015 and March 2016, after approval by the National Committee for Data Protection (Comissão Nacional de Proteção de Dados, Lisboa). SPEM invited 1930 of their members by postal mail to participate in the survey.
Results
A total of 535 evaluable responses were received (46 online, 489 on paper). All geographical regions were represented, reflecting population levels in these areas, except for Lisbon, that was slightly overrepresented (31% in the sample vs 21% in the population).
Age and EDSS in our samples drive the proportion of patients with relapsing disease indicated for DMT treatment, the number of patients actually on DMTs, to some extent the proportion reporting a relapse and the proportion of patients of working age. 5 The Portuguese respondents were among the younger groups in the European study, with a high proportion of patients of working age and a large group with early disease and consequently a high proportion on treatment with DMTs. Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in Portugal ranged from 20 to 80 years (mean: 48.5; median: 47.0; standard deviation (SD): 11.0); women represented 67%; 85% lived with their family; and only four patients were in a nursing home at the time of the survey. Education levels were slightly higher in comparison to the general population: 10% of patients had basic education, 48% a secondary or a professional degree and 39% a university degree of some type. This compares to 15% of the Portuguese population over 20 years of age who completed a university education (17% for women). 12 In the sample, 493 patients (92%) were below effective retirement age (66 years for women and 68 years for men 13 ) and of these, 43% patients were employed or self-employed at the time of the survey. Three patients above retirement age also worked, bringing this group to 216 patients (or 40% of the full sample) with a mean age of 42.6 years. It is difficult to relate this to the situation in Portugal, as employment rates are only published as a proportion of the total population (54.4% in 2015). 14 More than half of the patients worked part-time (58%) for an average of 13.2 hours/ week. This is considerably higher than in the general population where 14.4% of women and 10.6% of men worked part-time. 14 A total of 40% indicated that MS was the cause for part-time work.
Very few patients (N = 11; 5%) reported to be on long-term sick leave (>3 to ⩽12 months) or having had a short-term absence during the past 3 months (N = 16; 7%). Short-term sick leave lasted on average 16.9 days. Employment decreased rapidly with advancing disease, as shown in Figure 1 . MS was the reason for 77% of patients who were not employed.
Most patients felt that MS affected their productivity at work (72%) and only 13% indicated that they had no problems, while 14% had not answered the question. The severity of the effect covered the entire VAS range from 0 to 10, with a mean of 3.8 (SD: 2.8) ( Figure 2 ). Fatigue was considered the most bothersome symptom (71%), followed by difficulty thinking (31%), low mood (23%), mobility (23%) and pain (20%). Relapses in the preceding 3 months were reported by 96 patients (18%) of which slightly over half occurred in the past month (Table 1 ). However, 12% of respondents were unsure whether they had a relapse or not, and 4% did not answer the question. We assumed that the answer was no. The mean number of relapses over a period of 3 months in the sample was thus estimated at 0.2 (SD: 0.6). Corticosteroids were used by 52% of patients with relapses. Proportion of patients of working age employed or self-employed. Working age was defined as effective retirement age (66 years for women and 68 years for men; www.oecd.org). A total of 493 patients (92%) were below retirement age and of these, 43% were employed or self-employed. The group at EDSS 9 comprised only two patients, both below retirement age and not working.
Disease information

Symptoms and HRQoL
Fatigue was an issue for 98% patients who answered the VAS (N = 523). The mean score was 5.8 for the sample, and 5.1, 6.6 and 6.8 for patients with mild, moderate and severe disease, respectively ( Figure 2) .
Similarly, a majority of patients felt that they suffered from cognitive difficulties (74%). The mean VAS score among this group with issues was 5.3 and was correlated with disease severity: 4.8 in the mild, 5.4 in the moderate, and 6.0 in the severe group (Figure 2 ). For the full study sample (assigning 0 to the group with no problems), the mean score was 4.
Among the five domains of HRQoL included in the EQ-5D, only self-care did not represent problems for a majority of patients. Both the severity and the type of domain affected changed with advancing disease (Figure 3 ). 
Utility
Mean utility in the sample was 0.628 and 0.497 using the UK and Portuguese value sets, respectively, and declined with increasing EDSS (Figure 4 ).
Resource utilisation
Resource utilisation is presented in Community and social services were used by only 13% of patients in the past month, most frequently transportation. Help from family was used by 32% of patients, on average 19.9 days/month and 7.3 hours/ day. Services and informal care were concentrated in the group with severe disease ( Figure 5 ).
Costs
Total mean annual costs per patient for patients with mild, moderate and severe disease and by EDSS score are presented in Figure 6 and Table 4 .
The average cost of a relapse during a 3-month period was estimated at €2931, of which 74% were due to hospital care (Figure 7) .
Discussion
This study is an important contribution to the knowledge of the burden and management of MS in Portugal, where published material addressing these issues is very scarce. As a whole, these data represent a snapshot that may alert health professionals and governmental entities to difficulties encountered by patients and to the costs of MS in general, and thereby contribute to improving healthcare planning and resource allocation. The distribution of the disease types in our sample is somewhat different from what has been shown in other studies. In particular, the proportion of patients with RRMS is considerably lower than what has been observed in studies based on hospital cohorts (82%-85.3%). [15] [16] [17] This is not surprising as patients on treatment with DMTs, hence the majority with early and predominantly relapsing-remitting MS, are followed in hospitals. The sample in our study was recruited from a wider population in different settings, including therefore also more advanced patients. However, it is also known that patients find it difficult to judge their type of MS. Therefore, we used only EDSS and not disease type for our analyses and may assume that all disease types are represented, at least in the moderate group.
Healthcare costs are, as expected, dominated by the cost of DMTs, particularly in early disease. The mean annual cost per patient in our study increases threefold from €12,660 to €36,600 between EDSS 0 and EDSS 7, but decreases slightly at EDSS 8. This is entirely due to a much lower or no use of DMTs in the severe group that offsets the increase in community and informal care. The sample at EDSS 9 (two patients) is too small to draw any conclusion.
Among other healthcare resources, hospital care represents around 70% of the total at all levels of severity. This reflects the fact that patients with MS are mainly followed in public hospitals. Among non-medical direct costs, the low use of community services and the substantial rate of family help is representative of the pattern of socio-familial organisation and the Almost all patients in our sample are below retirement age (92%), but less than half of them continue working. The majority of those not working indicate that this is due to their disease. Patients appear to leave the workforce very rapidly, with the proportion working dropping from around 75% at EDSS 1-2 to 40% at EDSS 3. These results fit those obtained in a recent multicenter study where 74.1% of the nonactive MS population was retired due to disease. Additionally, the rates of activity and employment were similar to the general population in mildly incapacitated patients, but much reduced in patients with moderate and high incapacity. 18 Our data do not allow analysis of the reasons for early retirement from work, as many factors may contribute. The high level of fatigue is most certainly one factor, but the economic conditions with high unemployment in recent years (increased from 4% in 2004 to 14% in 2014) are likely to have played a role as well. Among patients not working because of MS, 75% receive an invalidity pension. In the general population, the proportions with invalidity pensions are 5.5%, 8.2% and 14.2% in the age groups 40-44, 45-49 and 50-54 years, respectively. 19 Overall, the number of people on invalidity pensions in the Portuguese population has decreased by more than half since 1990. 19 The comparison of our results with these national statistics illustrates the severity of MS and its very severe impact on working life.
When comparing the utility values by EDSS estimated with the recent Portuguese and UK value sets, the similarity of the curves is striking. The same results are seen in the other countries in our study that have developed a value set with the same method as Dolan et al. 9 in the United Kingdom. However, the Portuguese values are somewhat lower at all levels of EDSS.
In conclusion, information on the burden of illness in Portugal is limited. 20 This study provides the first comprehensive assessment of the burden of MS for Portuguese patients, the healthcare system and society overall.
